Inactive Instrument

All News Incannex Healthcare Australian S.E.

Equities

IHL

AU000000IHL8

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

Incannex Healthcare Inc. Quarterly Update, Q1 2024	Apr. 16	AQ
Incannex Healthcare Inc. Announces CFO Changes	Mar. 05	CI
Incannex Healthcare Inc. Announces Executive Changes	Mar. 05	CI
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	Feb. 28	CI
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	Feb. 28	AQ
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA	Feb. 16	MT
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation	Feb. 16	AQ
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N	Feb. 16	CI
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
Clarion Clinics Open for Psychedelic-Assisted Treatments	Feb. 01	AQ
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	Jan. 24	AQ
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	Jan. 24	CI
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences	Jan. 18	AQ
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder	Jan. 18	CI
Incannex Healthcare Gets Institutional Review Board Approval For IHL-42X Drug Trial	Jan. 17	MT
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	Jan. 17	AQ
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	Jan. 17	CI
Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia	Dec. 21	AQ
Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia	Dec. 21	CI
Incannex Healthcare : Change in Certifying Accountants - Form 8-K	Dec. 15	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Incannex Healthcare Australian S.E.

Equities

IHL

AU000000IHL8

All News

Filters